Dimensional Fund Advisors LP cut its holdings in shares of ResMed Inc. (NYSE:RMD – Get Rating) by 0.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 567,069 shares of the medical equipment provider’s stock after selling 4,656 shares during the quarter. Dimensional Fund Advisors LP owned about 0.39% of ResMed worth $118,026,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Achmea Investment Management B.V. lifted its position in shares of ResMed by 1.4% during the 4th quarter. Achmea Investment Management B.V. now owns 164,300 shares of the medical equipment provider’s stock valued at $32,041,000 after acquiring an additional 2,210 shares during the period. Huntington National Bank lifted its position in shares of ResMed by 197.2% during the 4th quarter. Huntington National Bank now owns 1,358 shares of the medical equipment provider’s stock valued at $283,000 after acquiring an additional 901 shares during the period. Treasurer of the State of North Carolina lifted its position in shares of ResMed by 1.4% during the 4th quarter. Treasurer of the State of North Carolina now owns 64,813 shares of the medical equipment provider’s stock valued at $13,490,000 after acquiring an additional 890 shares during the period. Royal London Asset Management Ltd. lifted its position in shares of ResMed by 5.5% during the 4th quarter. Royal London Asset Management Ltd. now owns 49,862 shares of the medical equipment provider’s stock valued at $10,376,000 after acquiring an additional 2,580 shares during the period. Finally, Citigroup Inc. lifted its position in shares of ResMed by 23.6% during the 4th quarter. Citigroup Inc. now owns 118,727 shares of the medical equipment provider’s stock valued at $24,711,000 after acquiring an additional 22,645 shares during the period. 64.73% of the stock is owned by institutional investors and hedge funds.
Insider Activity
In other news, CFO Brett Sandercock sold 3,426 shares of the stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $232.05, for a total value of $795,003.30. Following the completion of the sale, the chief financial officer now owns 103,516 shares of the company’s stock, valued at $24,020,887.80. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, insider Kaushik Ghoshal sold 500 shares of the firm’s stock in a transaction that occurred on Monday, May 1st. The stock was sold at an average price of $239.30, for a total transaction of $119,650.00. Following the completion of the sale, the insider now owns 12,704 shares of the company’s stock, valued at $3,040,067.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Brett Sandercock sold 3,426 shares of the firm’s stock in a transaction that occurred on Tuesday, May 9th. The stock was sold at an average price of $232.05, for a total value of $795,003.30. Following the sale, the chief financial officer now directly owns 103,516 shares of the company’s stock, valued at approximately $24,020,887.80. The disclosure for this sale can be found here. Over the last quarter, insiders sold 31,951 shares of company stock valued at $7,143,067. Company insiders own 1.39% of the company’s stock.
Wall Street Analyst Weigh In
ResMed Price Performance
ResMed stock opened at $224.51 on Friday. The company has a current ratio of 3.07, a quick ratio of 1.74 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $32.99 billion, a PE ratio of 38.25, a P/E/G ratio of 3.36 and a beta of 0.48. ResMed Inc. has a 12 month low of $192.85 and a 12 month high of $247.65. The stock has a 50-day moving average price of $222.83 and a two-hundred day moving average price of $219.97.
ResMed (NYSE:RMD – Get Rating) last posted its earnings results on Thursday, April 27th. The medical equipment provider reported $1.68 EPS for the quarter, beating the consensus estimate of $1.58 by $0.10. The firm had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.05 billion. ResMed had a return on equity of 25.82% and a net margin of 21.49%. The business’s quarterly revenue was up 29.2% on a year-over-year basis. During the same period last year, the company earned $1.32 earnings per share. Analysts expect that ResMed Inc. will post 6.48 EPS for the current year.
ResMed Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, June 15th. Stockholders of record on Thursday, May 11th will be paid a $0.44 dividend. The ex-dividend date of this dividend is Wednesday, May 10th. This represents a $1.76 annualized dividend and a dividend yield of 0.78%. ResMed’s payout ratio is 29.98%.
ResMed Company Profile
ResMed, Inc engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments.
Recommended Stories
- Get a free copy of the StockNews.com research report on ResMed (RMD)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.
